Panel · Use case · Clinical Operations

Enrollment Recovery Red Team.

LiveRed Team Review

Stress-test a trial enrollment recovery plan from operations, regulatory, safety and payer angles.

Plan under testAn enrollment recovery plan

AnglesOperations, regulatory, safety, evidence

ReaderClinical operations leads

Not askedA new timeline

DepthStandard, four seats

Enrollment Recovery Red Team is a ready-made use case for Clinical Operations. It ships under the Red Team Review template.

For clinical operations leads. You get the position under test, a verdict, the challenges by angle, which survive, what would have to be true and where the plan is weakest. Claims are cited or marked as gaps.

Add it to your library to reuse from New → From template. Edit the saved copy in your library on the service form.

The decision

Where does the recovery plan for a Phase 3 trial that is behind on enrollment fail, before it goes to the steering committee?

Who attacks

Recovery plans usually combine more sites, wider criteria and decentralized elements. Each carries its own risk to the analysis.

Seat	How it attacks	What it works from
Clinical Operations Director	Whether new sites and tactics can deliver on the timeline and the budget.	Site feasibility data and past recovery programs.
Regulatory Strategist	Which changes need an amendment and whether the agency will accept them.^{1U.S. Food and Drug Administration. Enhancing the Diversity of Clinical Trial Populations – Eligibility Criteria, Enrollment Practices, and Trial Designs: guidance for industry. November 2020.,2U.S. Food and Drug Administration. Conducting Clinical Trials With Decentralized Elements. Final guidance, September 2024.}	FDA guidance on eligibility and decentralized elements.
Head of Pharmacovigilance	Whether new populations or sites change the safety profile and monitoring burden.	Safety data for the class.
HEOR Evidence Lead	Whether the changes keep the result useful to payers.	The trial’s estimand and endpoints.

What the red team does

Each tactic has a cost to the analysis. Widening criteria changes who is studied; adding sites in new regions changes the population and the standard of care. The red team shows what each costs.^{1U.S. Food and Drug Administration. Enhancing the Diversity of Clinical Trial Populations – Eligibility Criteria, Enrollment Practices, and Trial Designs: guidance for industry. November 2020.}

Decentralized elements help some endpoints more than others. The red team checks which parts of the protocol can move to home or telehealth without harming data integrity.^{2U.S. Food and Drug Administration. Conducting Clinical Trials With Decentralized Elements. Final guidance, September 2024.}

Tripwires. The report lists the enrollment milestones at which the plan is declared failing, and what comes next.

Recommended length

Standard

Four angles can break this plan. Standard depth gives each a seat, scores the challenges and lists mitigations and tripwires in about four pages.

You can pick another length on the form. The other two stay available.

Assumptions the red team tests

The red team lists the assumptions the plan relies on and says what would break each. Examples for this plan:

The added sites will activate within the planned time.
The slow enrollment is not caused by competing trials in the same population.
The amendment will be approved without a pause.

Standards, guidance and sources

Frame

FDA, Enhancing the Diversity of Clinical Trial Populations – Eligibility Criteria, Enrollment Practices, and Trial Designs.^{1U.S. Food and Drug Administration. Enhancing the Diversity of Clinical Trial Populations – Eligibility Criteria, Enrollment Practices, and Trial Designs: guidance for industry. November 2020.}
FDA, Conducting Clinical Trials With Decentralized Elements, September 2024.^{2U.S. Food and Drug Administration. Conducting Clinical Trials With Decentralized Elements. Final guidance, September 2024.}

The decision practice behind the memo itself is on the template page.

What gets flagged

Any enrollment projection not supplied by the sponsor, any tactic with no owner, and any change that affects the primary analysis without a plan.

What arrives

The position under test
Verdict
The challenges, by angle
Which challenges survive
The pre-mortem
What would have to be true
Mitigations and tripwires
Where the position is weakest

What it will not do

It stays adversarial and does not defend the plan. It is a stress test by AI specialists and not a vote of human experts, and the decision stays with you.

It does not produce a new enrollment forecast.

It does not defend the plan. Defenses appear only as the status of an attack.

It does not invent an attack. Each challenge rests on a cited fact or is marked as a gap.

It is not a vote of human experts. Every seat is an AI specialist, and the report says so.

References

[1] U.S. Food and Drug Administration. Enhancing the Diversity of Clinical Trial Populations – Eligibility Criteria, Enrollment Practices, and Trial Designs: guidance for industry. November 2020. Title and date as known; not read.
[2] U.S. Food and Drug Administration. Conducting Clinical Trials With Decentralized Elements. Final guidance, September 2024. Definition as given in FDA’s announcement; not read in full.

Links checked 9 October 2026

These are the sources the template drew on. None of their authors or issuers has reviewed it.

About the Panel service

Each panelist answers in their own voice, then the discussion is drawn together. You get the question and who was in the room, every position in full, what they agreed on, where they split, and what follows. Disagreements are written down rather than smoothed into a consensus nobody actually holds, because the split is usually the part you needed.

To edit a saved template, open New → Panel → From template, or the library rail on the service form.